Novartis Completes Its Business Portfolio Restructuring, Divesting Gerber for US$5.5 Billion to Nestle
12. April 2007 01:52 ET
|
Novartis
* Divestiture program completed with Novartis business portfolio
now entirely focused on healthcare
* Joseph Jimenez named new CEO of Consumer Health division
BASEL, Switzerland, April 12,...
Novartis Announces Initiative to Improve Access to State-of-the-Art Anti-Malarial Treatment Coartem
29. September 2006 01:10 ET
|
Novartis
-- Malaria strikes 300 million to 500 million people every year, the
biggest killer of children in Africa -- every 30 seconds a child
in Africa dies of this disease
-- Average cost per...
Novartis Awarded Up to USD220 Million by U.S. Department of Health and Human Services for Development of Cell Culture-Derived Influenza Vaccine
04. Mai 2006 10:41 ET
|
Novartis
-- Novartis Vaccines leadership in new cell-culture based influenza
vaccine development acknowledged
-- Importance of new technologies recognized by U.S. government to
provide quick and...
Novartis Delivers Strong Start to 2006 in First Quarter with Excellent Sales and Earnings Growth Performance
24. April 2006 02:48 ET
|
Novartis
BASEL, Switzerland, April 24, 2006 (PRIMEZONE) --
-- Group first quarter net sales up 13% in USD (+17% in local
currencies) based on strong underlying sales expansion in all
...
New Drug Application for Rasilez, an Innovative Oral Renin Inhibitor to Treat High Blood Pressure, Accepted for U.S. Regulatory Review
20. April 2006 01:44 ET
|
Novartis
BASEL, Switzerland, April 20, 2006 (PRIMEZONE) --
-- Renin inhibitors would be the first new class of high blood pressure
medicines available in more than 10 years
-- U.S. Submission...
Novartis Delivers Strong Performance with Record Results in 2005
19. Januar 2006 01:30 ET
|
Novartis
-- Group full-year net sales up 14% in USD (+13% lc) thanks to
dynamic expansion of Novartis Pharmaceuticals and Sandoz, the
latter supported by acquisitions
-- Pharmaceuticals...
Novartis Announces Leadership of New Vaccines and Diagnostics Business
03. November 2005 01:58 ET
|
Novartis
BASEL, Switzerland, Nov. 3, 2005 (PRIMEZONE) -- Novartis (NYSE:NVS) announced today that it has designated Dr. Joerg Reinhardt, currently Global Head of Pharma Development, to become CEO of a new...
Novartis Announces Agreement to Acquire Remaining Stake in Chiron
31. Oktober 2005 04:45 ET
|
Novartis
-- Acquisition provides Novartis with attractive growth platforms in
the dynamic vaccines market and in a rapidly growing molecular
diagnostic business
-- Biopharmaceutical activities...
Novartis Delivers Strong Growth in First Nine Months of 2005 on Track to Achieve Full-Year Sales and Earnings Objectives
18. Oktober 2005 01:44 ET
|
Novartis
-- Group nine-month net sales rise 14% in USD (+12% lc), thanks to
strong underlying growth and market share gains in all divisions
-- Pharmaceuticals growth of 11% (+9% lc) for first nine...
Novartis: FTY720 Phase II 12-month Data Show Sustained Benefits and Good Tolerability in Patients with Relapsing Multiple Sclerosis
01. Oktober 2005 03:11 ET
|
Novartis
BASEL, Switzerland, Oct. 1, 2005 (PRIMEZONE) -- Data from the extension of a Phase II study to 12 months confirm the significant effects of FTY720, a novel oral medication, for the treatment of...